Table 3.
Cardiovascular events in patients with COVID-19 who survived and did not survive to hospital discharge
| Survived to hospital discharge |
|||
|---|---|---|---|
| Endpoint | Yes (n = 504) |
No (n = 82) |
p-value for difference |
| MACE | 83 (16.5%) | 52 (63%) | <0.001 |
| Ischemic | |||
| Type 1 myocardial infarction | 1 (0.2%) | 2 (2%) | 0.05 |
| Type 2 myocardial infarction | 22 (4.4%) | 22 (27%) | <0.001 |
| Isolated myocardial injury | 46 (9.1%) | 18 (22%) | <0.001 |
| Stroke | 4 (0.8%) | 7 (9%) | <0.001 |
| Heart failure | |||
| New acute decompensated heart failure | 16 (3.2%) | 15 (18%) | <0.001 |
| Worsening acute decompensated heart failure | 19 (3.8%) | 16 (20%) | <0.001 |
| Cardiogenic shock | 4 (0.8%) | 8 (10%) | <0.001 |
| Myocarditis | 0 | 0 | - |
| Stress (takotsubo) cardiomyopathy | 4 (0.8%) | 0 | 0.55 |
| Arrhythmia | |||
| New-onset atrial fibrillation or atrial flutter | 27 (5.4%) | 19 (23%) | <0.001 |
| New-onset ventricular arrhythmia | 14 (2.8%) | 5 (6%) | 0.12 |
| Venous | |||
| Pulmonary embolism or deep vein thrombosis | 19 (3.8%) | 15 (18%) | <0.001 |
| Other | |||
| Pericardial effusion or cardiac tamponade | 2 (0.4%) | 3 (4%) | 0.02 |
| Aborted cardiac arrest | 5 (1.0%) | 16 (20%) | <0.001 |
MACE = major adverse cardiovascular events.